Analysts Set United Therapeutics Co. (NASDAQ:UTHR) Target Price at $326.42

Shares of United Therapeutics Co. (NASDAQ:UTHR) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $331.73.

A number of research firms recently issued reports on UTHR. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. LADENBURG THALM/SH SH downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. TD Cowen boosted their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Wells Fargo & Company upped their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Finally, JPMorgan Chase & Co. lifted their price target on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $264.22, for a total transaction of $951,192.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $34,348.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $264.22, for a total value of $951,192.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $34,348.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Patusky sold 1,310 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $264.35, for a total value of $346,298.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 103,644 shares of company stock valued at $31,558,715. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. LSV Asset Management boosted its stake in United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after acquiring an additional 436,851 shares in the last quarter. Paralel Advisors LLC acquired a new position in shares of United Therapeutics during the second quarter valued at about $3,165,000. Caprock Group LLC bought a new position in shares of United Therapeutics during the 2nd quarter worth about $221,000. Los Angeles Capital Management LLC grew its stake in shares of United Therapeutics by 11.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 99,328 shares of the biotechnology company’s stock valued at $31,641,000 after buying an additional 10,476 shares during the period. Finally, Candriam S.C.A. increased its position in United Therapeutics by 2,094.3% in the 2nd quarter. Candriam S.C.A. now owns 64,513 shares of the biotechnology company’s stock valued at $20,550,000 after buying an additional 61,573 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $321.96 on Friday. The stock has a market cap of $14.28 billion, a P/E ratio of 15.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.55. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $343.98. The stock’s 50-day moving average price is $310.44 and its two-hundred day moving average price is $263.02. The company has a current ratio of 4.35, a quick ratio of 3.64 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same period in the previous year, the business earned $5.24 EPS. The firm’s revenue was up 19.8% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics will post 25.4 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.